Showing posts with label Sales. Show all posts
Showing posts with label Sales. Show all posts

Wednesday, 18 September 2013

Microsoft kicks off iPad buyback deal in latest effort to juice Surface sales

Microsoft will pay at least $200 for used iPads made by rival Apple, and in return issue credit that customers can use to buy one of the company's Surface tablets.

On its Microsoft Store website, Microsoft outlined the buyback deal: It will accept "gently used" iPad 2, and third- and fourth-generation iPads -- the latter two models launched in 2012 -- pay a minimum of $200 for each tablet, and issue the funds as a gift card good for purchases at the Microsoft Store.

[ Also on InfoWorld: Surface 2 leaked details paint lackluster picture. | Get expert advice about planning and implementing your BYOD strategy with InfoWorld's 29-page "Mobile and BYOD Deep Dive" PDF special report. | Keep up on key mobile developments and insights with the Mobilize newsletter. ]

Customers must bring their used iPads to a Canadian or U.S. Microsoft retail outlet -- the program's not supported online -- where a sales person will evaluate the tablet and decide on the dollar amount. Microsoft has approximately 70 stores in the U.S.

Apple's 7.9-in. iPad Mini is not eligible for trade-in.

"Microsoft Store gift-card value ... is subject to Microsoft's discretion and manager approval," the website said. "All trade-ins are final. Limit 1 per customer."

Because the buyback program isn't available online, it's impossible to tell what Microsoft will pay for an iPad before going to a store. Re-commerce vendors such as Gazelle and NextWorth pay between $150 and $240 for a working 16GB Wi-Fi-only iPad, with the lower value for the 2011 iPad 2 and the upper-end for the newest fourth-generation "Retina"-equipped device.

Buyback companies pay more for iPads with more storage space or those equipped for accessing the Internet over a mobile carrier data network.

They also pay cash for the Surface RT and Surface Pro tablets made by Microsoft. NextWorth quoted $187 for a 32GB Surface RT and $338 for the entry-level 64GB Surface Pro, or 54% and 43% of the list price, respectively. Microsoft's tablets start at $349 for the Surface RT, the struggling model powered by Windows RT, a subset of the more powerful Windows 8 that can run only so-called "Metro" apps. The Surface Pro, which relies on Windows 8 and can run legacy software like the desktop version of Office 2013, starts at $799.

The Redmond, Wash. company has cut prices of both models in the last two months to account for over-optimistic inventory plans and to clear the decks before Sept. 23, when it will unveil new models for the holiday selling season.

The resulting gift cards from an iPad trade-in do not have to be used for the purchase of a Microsoft Surface, but can be redeemed for anything Microsoft sells in its stores, including third-party PCs.

The deal also offers a call for action to iPad owners who have been swayed by Microsoft's television campaign that compare various features of the Surface RT with the 9.7-in. iPad, which starts at $499 with 16GB of storage space.

Microsoft's iPad buyback program expires Oct. 27. Apple is expected to roll out new tablets this year, and if it follows last year's practice -- when it also unveiled a new iPhone in September, as it did earlier this week -- the most likely introduction date is Tuesday Oct. 22.

Gregg Keizer covers Microsoft, security issues, Apple, Web browsers and general technology breaking news for Computerworld. Follow Gregg on Twitter at @gkeizer, or subscribe to Gregg's RSS feed . His email address is gkeizer@ix.netcom.com.

Read more about mobile/wireless in Computerworld's Mobile/Wireless Topic Center.


View the original article here

Sunday, 8 September 2013

Federal judge upholds Apple's 30% take on in-app e-book sales

Computerworld - A federal judge on Thursday rejected government regulators' demand that Apple waive its 30% commission on all in-app e-book sales by third-party retailers, including Amazon, for two years.

Instead, Judge Denise Cote ruled that Apple could continue to bar e-book apps from its iOS App Store if the programs included links to external websites where customers could buy books or subscriptions.

Cote, who has presided over the e-book price-fixing case against Apple, issued her final injunction Thursday. Under that injunction, Apple is prohibited from disclosing deals it strikes with one e-book publisher to others -- a way to prevent it from again conspiring to set industry-wide prices -- and its behavior will be monitored for two years by a court-appointed antitrust compliance officer.

Her rejection of the Department of Justice's (DOJ) proposal that Apple be required to change its App Store policies, however, was a victory of sorts for Apple.

"Apple shall apply the same terms and conditions to the sale or distribution of an E-book App through Apple's App Store as Apple applies to all other apps sold or distributed through Apple's App Store," Cote ruled.

"This provision does not prevent Apple from introducing new categories of apps with different terms and conditions or from changing its App Store terms and conditions and applying them in a reasonable manner as long as Apple does not discriminate against E-book Apps," she wrote in the final injunction.

In early August, after Cote had found Apple guilty of violating antitrust laws, the DOJ and 33 state attorneys general had proposed a suite of remedies to ensure Apple could not become a repeat offender. Among them was a demand that e-book retailers be allowed to include links to external sales websites in their iPhone and iPad apps, a move that would have let the retailers sidestep Apple's 30% commission on all in-app revenue.

The DOJ and state attorneys general said that the commission exemption would "reset competition to the conditions that existed before the conspiracy" and "let consumers ...easily compare Apple's prices with those of its competitors."

Apple opposed the change, arguing last month that the government's App Store dictates had no connection to the e-book pricing conspiracy case, and that such interference in its business practice was "outrageous."

"Plaintiffs' proposed injunction would require Apple to carve out an exception to its blanket rule -- applicable to the more than 850,000 apps in the App Store -- that a commission applies to in-app sales of digital goods, and it would allow e-book retailers to make such sales commission-free," Apple's lawyers said in an August filing with the court.

Apple also made an implied threat, saying it was "under no duty to allow other retailers to offer apps on the iPad in the first place, much less on terms that subsidize their operations." That threat was effectively hollow, however, since an earlier order by Cote had blocked Apple from dumping e-book apps from the App Store.

Cote will decide on what damages Apple must pay in early 2014. Some e-book retailers, including Amazon, have told customers that they can expect between 73 cents and $3.06 for every eligible e-book purchased between April 1, 2010, and May 21, 2012, based on already-struck settlements with the book publishers.

Apple has said it will appeal Cote's July antitrust ruling.

Gregg Keizer covers Microsoft, security issues, Apple, Web browsers and general technology breaking news for Computerworld. Follow Gregg on Twitter at Twitter @gkeizer, on Google+ or subscribe to Gregg's RSS feed Keizer RSS. His email address is gkeizer@computerworld.com.

See more by Gregg Keizer on Computerworld.com.

Read more about Legal in Computerworld's Legal Topic Center.

How Cloud Communications Reduce Costs and Increase ProductivitySmall and midsize businesses are moving to the cloud to host their communications capabilities. Learn how enterprise-quality phone benefits, online management, conferencing, auto attendant, and ease of use are built into a system that is half the cost of a PBX.

Read now.


View the original article here

Monday, 12 August 2013

Merck's Pipeline Of Drugs Should Make Up For Lost Sales To Generic Competition

Merck & Co., Inc. (MRK): Merck's Pipeline Of Drugs Should Make Up For Lost Sales To Generic Competition - Seeking Alpha (function(_,e,rr,s){_errs=[s];var c=_.onerror;_.onerror=function(){var a=arguments;_errs.push(a); c&&c.apply(this,a)};var b=function(){var c=e.createElement(rr),b=e.getElementsByTagName(rr)[0]; c.src="//beacon.errorception.com/"+s+".js";c.async=!0;b.parentNode.insertBefore(c,b)}; _.addEventListener?_.addEventListener("load",b,!1):_.attachEvent("onload",b)}) (window,document,"script","4ffae9d6f05d1da630000008"); if (SA.Data && SA.Data.Cache) { var adata = SA.Data.Cache.get('campaign_content'); }.market_currents_list li .ticker_date_left .mc_list_tickers a{font-weight: normal} var ms_slug = ''; var article_dashboards = '@investing-ideas@sectors@'; var article_sectors_themes = '@long-ideas@us@drug-manufacturers-major@healthcare@article@'; var ratings_hash={}; var ARTICLE_ID = 1628062; var ARTICLE_TYPE = "standard"; var ARTICLE_LOCK = ""; var author_slug = "glen-s-woods"; var pticker_for_ads = "mrk"; var lock_comments = false; var machine_cookie = readCookie('machine_cookie'); var middle_version = ABTest.identity%10; try { window.sessionStorage.setItem("/article/"+ARTICLE_ID, '1'); } catch (error) {}var mone_article_tags = "{mrk};;;{healthcare};;;{long-ideas,us,drug-manufacturers-major,investing-ideas,sa-exclusive};;;{glen-s-woods}"var ord = Math.floor(Math.random()*1000000000);Seeking Alpha Seeking Alpha Portfolio App for iPad Finance (1) var ipadData; SeekingAlpha.Initializer.AddAfterLoad(function(){ if (SA.Utils.Env.isIPad && !/3/.test(SA.Data.Cookies.get("user_devices"))){ Mone.event("ipad_promotion_top","top_ipad_banner_large","ipad_promotion_displayed"); ipadData = new SA.Data.iPad(); ipadData.instanceName = "ipadData"; var responseHandler = new Object(); responseHandler.handleResponse = function(data){ if (!data.averageUserRating) return; var stars = data.averageUserRating Home | Portfolio | Market Currents | Investing Ideas | Dividends & Income | ETFs | Macro View | ALERTS | PRO   This article was sent to 14,242 people who get email alerts on  . Which cover: new articles | breaking news | earnings results | dividend announcements Get email alerts on   » This article was sent to 329,584 people who get the Investing Ideas newsletter. Get the Investing Ideas newsletter » Comments () This article has  comments. To read them or add your own, click here. Download the Free Seeking Alpha Portfolio App Now! The #1 Portfolio App is Now on iPad! Get instant notifications & never miss a critical update on your stocks! Which Seeking Alpha App is best for you? Seeking Alpha Portfolio Tech Investor ETF investor Energy Investor Email me a link to open from my phone: Continue Merck's Pipeline Of Drugs Should Make Up For Lost Sales To Generic Competition Aug 12 2013, 08:28 by: Glen S. Woods |  about: MRK (Merck & Co., Inc.)

Though Merck & Co (MRK) has seen its stock rise over 18% YTD, the giant drug maker has seen some setbacks as the company has experienced a drop in drug sales due to generic competition. While some pundits see Merck's stock trading sideways until the company develops a new blockbuster, there are a number of positive happenings at Merck that make the stock attractive over the long term. In the second quarter the company has seen a rise in sales of eight of its top selling drugs; plus due to its billions of dollars the company spends yearly in research and development it also has one of the strongest pipelines of drugs in various stages of testing.

MERCK'S PIPELINE

Merck spent nearly $8 billion in research and development in 2012 with a goal of developing future blockbuster drugs. Today the company has developed an extensive pipeline of 44 drugs in various stages of testing, including 6 that are under review waiting for approval from the U.S. Food and Drug Administration (FDA), and 15 in Phase III studies. However, there have been setbacks and delays, such as with the osteoporosis drug, odanacatib, which the company had hoped to file for FDA approval in the first half of 2013, but now expects to file sometime in 2014 in order to provide additional safety and efficacy data. If odanacatib does gain approval by the FDA, Barclays Capital projects peak annual sales of over $2 billion by 2020

Another promising drug that has been given "breakthrough status" in late April by the FDA is lambrolizumab (MK-3475) for the treatment of melanoma and non-small cell lung cancer. Lambrolizumab received "breakthrough status" when the FDA acknowledged that the drug was able to demonstrate major benefits over the current therapies offered for the life-threatening illnesses. Merck has four clinical studies underway for lambrolizumab for a variety of cancers, including a Phase II study for melanoma, and Phase I trials with Bristol-Myers Squibb's (BMY) Yervoy for patients suffering from triple-negative breast cancer, metastatic bladder cancer, and head and neck cancer. Analysts at Leerink Swann estimate that lambrolizumab could generate peak sales of $450 million in just the melanoma indication by 2023.

SECOND QUARTER SALES

What mostly has investors concerned is Merck's second quarter drop in sales. Sales slid 11% to $11.01 billion, due mostly to its once top asthma drug, Singulair, tumbling 80% from $1.43 billion in the second quarter 2012 to just $281 million in the second quarter 2013. Singulair was once the eleventh best-selling drug in the world; however since it went off patent last fall the drug has experienced a free fall in sales. This led to the company's second quarter earnings to fall to $906 million, or $0.30 a share, down from 2012-second quarter of $1.79 billion, or $0.58 a share. However, there is hope that some of the drugs in its pipeline will eventually offset the losses in sales from Singulair and other drugs that have gone or will go off patent.

The company did experience a rise in sales of some of its drugs, including its popular diabetes drugs-- Janumet, which grew 16% to $474 million, and Januvia, which saw sales rise a modest 1% to $1.1 billion. Januvia sales have recently felt pressure from Johnson & Johnson's (JNJ) competing drug, Invokana , which was approved by the FDA for type 2 diabetes earlier this year. Invokana treats diabetes differently compared to many other diabetes drugs, including Januvia, by causing blood sugar to be excreted in the urine, but it may also have more serious side effects including elevated stroke risk and raising LDL (the bad cholesterol) levels.

Sales of the company's cervical cancer vaccine, Gardasil, jumped 18% on revenues of $383 million compared to $323 million in the same quarter 2012, while cholesterol lowering medicine, Zetia, rose 3% to $650 million up from $470 million in second quarter 2012. Vytorin (another cholesterol medication) sales dropped 6% to $417 million down from $445 million in 2012. Remicade, used to treat Crohn's and other inflammatory diseases, had sales growth of 2% to $527 million up from $518 million. Isentress, an HIV integrase inhibitor for use in combination with other antiretroviral agents, grew 4% to $412 million.

MERCK STOCK STILL HAS ROOM TO GROW

Merck has a market cap of $145.9 billio. The company has more than $13 billion in cash in its arsenal. Merck also announced a dividend of $0.43 per share on September 16th, representing a $1.72 dividend on an annualized basis and a yield of 3.54%. In an effort to prop up investors' value in the stock, Merck announced in mid-May that it planned to repurchase $5 billion in company stock from Goldman Sachs (GS), which comes to roughly 99.5 million shares. Add to that the company already authorized additional purchases of up to $15 billion of its common stock and intends to buy back about $7.5 billion over the next 12 months.

On August 5th, The Street reiterated a buy rating due to its "solid financial position with reasonable debt levels." On July 31st, Zacks reissued a neutral rating and maintained its $50.00 target price. Separately, analysts at BMO Capital Markets downgraded Merck from an outperform rating to a market perform rating with a $51.00 price target on the stock. On July 12th, analysts at Jefferies Group reiterated a buy rating but lowered its target price from $56.00 per share to $54.00 per share.

CONCLUSION
Though investors should be cautious about the sales outlook and short-term growth for Merck, I think the company's outlook for the future is promising and strong. For the long term, to make up the lost revenue from generic competition, Merck does need a blockbuster drug from either its own pipeline or from a collaboration with a smaller biopharmaceutical company. Merck has plenty of cash to make such a collaboration happen if the opportunity arises. Though there are other giant pharmaceutical companies that are strong investments today, I think Merck is a solid stock to have in one's long term portfolio.

Source: Merck's Pipeline Of Drugs Should Make Up For Lost Sales To Generic Competition

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More...)

SA.Pages.Article.handleDisclosures(); This article was sent to 14,242 people who get email alerts on  . Get email alerts on   » This article was sent to 329,584 people who get the Investing Ideas newsletter. Get the Investing Ideas newsletter » Comments () This article has  comments. To read them or add your own, click here. Download the Free Seeking Alpha Portfolio App Now! The #1 Portfolio App is Now on iPad! Get instant notifications & never miss a critical update on your stocks! Which Seeking Alpha App is best for you? Seeking Alpha Portfolio Tech Investor ETF investor Energy Investor Email me a link to open from my phone: Continue 14,242  people received this article by email alert
Add your email to get alerts on   too: Get email alerts on   » This article was sent to 329,584 people who get the Investing Ideas newsletter. Get the Investing Ideas newsletter » Tagged: Investing Ideas, Long Ideas, Healthcare, Drug Manufacturers - Major Share this article Short URL: Tweet SeekingAlpha.Initializer.AddAfterLoad(function(){ new Ajax.Updater({success: 'widget_email_count'}, '/form/ajax_get_email_count', { method: 'get', parameters: { item_name: 'Article', article_id: '1628062' } }); }); var author_info_popup_timeout; Glen S. Woods picture About the author: Glen S. Woods Glen S. Woods picture I have been a professional writer for over 20 years. I also have enjoyed searching micro and nano cap companies looking for hidden gems. Having grown up around stock brokers and commodities traders I have seen the business from both sides. I have been an investor in the market for most of my life. Glen S. Woods Articles (24) Comments (21) if (/stats viewer/.test(readCookie("user_perm"))) document.write("Earnings"); Profile 61 Followers 2 Following Follow.author_sidebar__follow_button_initiator('glen-s-woods') Send Message

Glen S. Woods

Stop Following

Glen S. Woods

SeekingAlpha.Initializer.onDOMLoad(function (){Follow.setFfToElements($('followers'),$('followings'),48951)}) if (getURLParam('source') == 'yahoo'){ $('yahoo_finance_link_container').innerHTML = 'back to yahoo finance'; } var page_ad_src = 'http://ad.doubleclick.net/adj/sek.investing-ideas/long-ideas;sz=300x251;x=x;tile=4;d=investing-ideas;pos=b;t=long-ideas;aid=1628062;d=investing-ideas;d=sectors;t=long-ideas;t=us;t=drug-manufacturers-major;t=healthcare;t=article;a=glen-s-woods;cnt=7;cnt=5;cnt=20;cnt=25;pr=mrk;s=mrk;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'; add_js_to_ad_call('http://ad.doubleclick.net/adj/sek.investing-ideas/long-ideas;sz=300x250,300x600;x=x;tile=2;d=investing-ideas;pos=t;t=long-ideas;aid=1628062;d=investing-ideas;d=sectors;t=long-ideas;t=us;t=drug-manufacturers-major;t=healthcare;t=article;a=glen-s-woods;cnt=7;cnt=5;cnt=20;cnt=25;pr=mrk;s=mrk;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'); SA.Utils.Ads.add({el:$('article_dart_sticky'), HadCreated:false, size:'300x250', delta:50, info:'http://ad.doubleclick.net/adj/sek.investing-ideas/long-ideas;sz=300x251;x=x;tile=4;d=investing-ideas;pos=b;t=long-ideas;aid=1628062;d=investing-ideas;d=sectors;t=long-ideas;t=us;t=drug-manufacturers-major;t=healthcare;t=article;a=glen-s-woods;cnt=7;cnt=5;cnt=20;cnt=25;pr=mrk;s=mrk;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'}); if (SA.Pages.Article.see_sb_promo()){ var delegateObj = new Object(); SA.Utils.Ads.setDelegateIframeAction(delegateObj); delegateObj.loadIframeForElement = function(el) { if (el.id == "article_dart_sticky") setTimeout("SA.Pages.Article.freeze_arich_promo()",3000); } } TOP AUTHORS: The Opinion Leaders TOP USERS: StockTalkers | Instablogs Follow us Follow us Mobile Apps  |      RSS Feeds  |  About Us  |  Contact Us Terms of Use | Privacy | Xignite quote data | © 2013 Seeking Alpha document.observe('dom:loaded', function(){ if ($('article_source')) {$('article_source').hide();} if (!is_pro) {$$('.arich_promobox').each(function(o){o.show()})} SA.Pages.Article.primary = "mrk"; SA.Pages.Article.init(); if (typeof(propromotion) != "undefined") {propromotion();} if (SA.Pages.Article.alpha_rich_article() || SA.Pages.Article.insiders_report_article()){ update_pro_tracker(0,1,0,0); } if (location.href.match(/source=[a-z0-9_]*email[a-z0-9_]*/)) {createCookie('camefromrta',true);} var pagination_version = ABTest.identity%10; if (SA.Pages.Article.is_roadblock()){ rb = new roadblock('article'); rb.register_show = SA.Pages.Article.roadshow; Mone.event(rb.type,rb.source,"Half Article"); SA.Pages.Article.cut_new(pagination_version); } else { if (!SA.Data.User.loggedIn() && (location.search.match(/[?&]source=(yahoo|nasdaq)/)) && !document.cookie.match(/\b(user_id|user_email|camefromrta)=/)) { SA.Pages.Article.hide_features_for_roadblock(); } } }); SeekingAlpha.Initializer.AddAfterLoad(function(){ SA.Pages.Article.articlePromo({"allSlugs":["mrk"],"primarySlug":"mrk","dashboard_id":10727,"dashboard_title":"Investing Ideas"}); }); var time_left; function calculate_new_datetime() { time_left = time_left - 1; if (time_left > 0) { this_clock = $("aritcle_timer").update(article_clock(time_left)); } else { $('article_header').className = "article_content"; this_clock.parentNode.removeChild(this_clock); clearInterval(run_clock_every_minute) } } var article_clock=function(time_left){ var container=document.createElement('div'); var scale=document.createElement('div'); var clock=document.createElement('div'); var hour=document.createElement('div'); var min=document.createElement('div'); var colon=document.createElement('div'); var time_left=parseInt(time_left); container.className='timer_container'; scale.className='scale'; clock.className='clock'; hour.className='hour'; min.className='min'; colon.className='colon'; container.appendChild(scale); clock.appendChild(hour); clock.appendChild(colon); clock.appendChild(min); container.appendChild(clock); article_clock.updateTime=function(timeLeft){ var h=parseInt(timeLeft/60); var m=parseInt(timeLeft%60); var arr_pos=parseInt((1440-timeLeft)/60); hour.innerHTML=h 0) { this_clock.appendChild(article_clock(time_left)); run_clock_every_minute = setInterval(calculate_new_datetime, 60000); }

View the original article here